Table 2.
Serum and BALF MMP concentrations
| IPF | COPD | Control | p-value | p-value | p-value | |
|---|---|---|---|---|---|---|
| (n = 57) | (n = 20) | (n = 15) | IPF vs. Control | IPF vs. COPD | COPD vs. Control | |
| Serum | ||||||
| MMP-1, ng/mL | 1.52 ± 1.36 | 0.95 ± 0.74 | 0.60 ± 0.58 | 0.005 | NS | NS |
| MMP-2, ng/mL | 73.5 ± 60.8 | 27.6 ± 11.8 | 41.3 ± 40.6 | 0.034 | <0.001 | NS |
| MMP-3, ng/mL | 8.43 ± 10.51 | 4.54 ± 2.26 | 3.78 ± 3.00 | NS | NS | NS |
| MMP-7, ng/mL | 8.39 ± 4.32 | 1.72 ± 0.65 | 2.14 ± 1.41 | <0.001 | <0.001 | NS |
| MMP-8, ng/mL | 1.43 ± 1.50 | 0.80 ± 0.62 | 0.47 ± 0.51 | 0.012 | NS | NS |
| MMP-9, ng/mL | 38.7 ± 26.8 | 23.3 ± 15.7 | 25.9 ± 24.0 | NS | 0.030 | NS |
| MMP-10, ng/mL | 1.18 ± 0.83 | 0.16 ± 0.18 | 0.18 ± 0.18 | <0.001 | <0.001 | NS |
| MMP-12, ng/mL | 0.31 ± 0.23 | 0.17 ± 0.11 | <0.1a | <0.001 | 0.013 | <0.001 |
| MMP-13, ng/mL | <0.1a | <0.1a | <0.1a | |||
| KL-6, U/mL | 1084.2 ± 724.4 | – | – | |||
| SP-D, ng/mL | 300.4 ± 223.7 | – | – | |||
| BALF | ||||||
| MMP-7, ng/mL | 9.6 ± 10.7 | – | – | |||
| MMP-10, ng/mL | 0.10 ± 0.09 | – | – |
The data are presented as the mean ± standard deviation
IPF idiopathic pulmonary fibrosis, COPD chronic obstructive pulmonary disease, MMP matrix metalloproteinase, NS not significant, KL-6 Krebs von den lungen-6, SP-D surfactant protein-D, BALF bronchoalveolar lavage fluid
aThe mean is under the limit of determination